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Abstract
The epithelial-to-mesenchymal transition (EMT) enables carcinoma cells to acquire malignancy-
associated traits and properties of tumor-initiating cells (TICs). TICs have emerged in recent years 
as important targets for cancer therapy owing to their ability to drive clinical relapse and enable 
metastasis. Here we propose a strategy to eliminate mesenchymal TICs by inducing their 
conversion to more epithelial counterparts that have lost tumor-initiating ability. We report that 
increases in intracellular levels of the second messenger, cAMP, and the subsequent activation of 
protein kinase A (PKA) induce a mesenchymal-to-epithelial transition (MET) in mesenchymal 
human mammary epithelial cells. Activation of PKA triggers PHF2-mediated epigenetic 
reprogramming of TICs, promoting their differentiation that leads to loss of tumor-initiating 
ability. This study provides proof-of-principle for inducing an MET as differentiation therapy for 
TICs and uncovers a novel role for PKA in enforcing and maintaining the epithelial state.
One Sentence Summary
We identify a novel role for the activation of PKA and downstream epigenetic reprogramming that 
results in the differentiation of tumor-initiating cells in aggressive breast cancers.
Introduction
Tumor-initiating cells (TICs), also known as cancer stem cells, are defined operationally by 
their ability to seed new tumors upon implantation in appropriate hosts. They have emerged 
in recent years as important targets for cancer therapy owing to their elevated resistance to 
conventional chemotherapy and their tumor-initiating ability; the latter allowing them to 
metastasize and drive clinical relapse (1, 2). While their mode of generation and biological 
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properties have been explored in a diverse array of cancer types (3), our understanding of the 
biology of TICs remains superficial. Cytotoxic therapies designed specifically to eliminate 
TICs might be targeted, for example, to interdict the signaling pathways that are used 
preferentially or uniquely by these cells (4). At present, however, the nature of such TIC-
specific signaling pathways remains to be fully elucidated.
The epithelial-to-mesenchymal transition (EMT) is a cell-biological program that confers 
mesenchymal traits on both normal and neoplastic epithelial cells (5). In addition, activation 
of an EMT program enables both classes of cells to acquire stem-like properties (6, 7). 
Indeed, TICs from several carcinoma types possess distinct mesenchymal attributes, 
suggesting that they have passed, at least partially, through an EMT (7–9). This association 
between the EMT program and the TIC state has presented an attractive opportunity for drug 
development, using agents that preferentially target more mesenchymal carcinoma cells 
rather than their epithelial counterparts in an effort to eliminate TICs.
At least two approaches might be taken to target mesenchymal TICs. One strategy would be 
to develop agents that show specific or preferential cytotoxicity toward TICs (1). In this 
study, we have embraced an alternative strategy that is designed to induce TICs to exit the 
more mesenchymal tumor-initiating state and enter into an epithelial non-stemlike state. 
Such induced differentiation should, we reasoned, place cells in a state where they would 
become more vulnerable to conventional cytotoxic treatments. Accordingly, we screened for 
agents that could induce a mesenchymal-to-epithelial transition (MET) and thereby 
uncovered the central role of 3’-5’-cyclic adenosine monophosphate (cAMP) and its 
downstream target, protein kinase A (PKA), in governing the transition of cells from the 
mesenchymal to the epithelial state.
cAMP is a second messenger that transmits intracellular signals upon interaction of certain 
hormones and neurotransmitters with receptors on the plasma membrane (10). cAMP 
regulates multiple downstream effectors; the first of these to be identified and the most well-
studied is protein kinase A (PKA) (11), which plays numerous roles in various cell types and 
operates in several subcellular locations (11). Being initially assembled as a heterotetrameric 
holoenzyme, the activity of PKA depends on binding of cAMP to its two regulatory 
subunits, which leads to the release of active catalytic subunits and the phosphorylation of a 
diverse array of substrates (12).
In previous work, PKA has been shown, under some conditions, to promote an EMT; PKA 
was shown to regulate Snail in one study and another study demonstrated that HIF1α could 
regulate transcription of PRKACA under hypoxic conditions (13, 14). On the other hand, 
PKA signaling has been shown to favor the epithelial state, but the mechanistic 
understanding of this phenomenon is very limited. One report identified that schwannomas 
in Prkar1a (encoding the PKA regulatory subunit)-null mice exhibited loss of vimentin and 
gain of cytokeratins and E-cadherin (15), whereas another study revealed inhibition of 
formation of mesoderm-derived structures in Prkar1a null mice (16). A recent study reported 
that deletion of the Gαs subunit repressed the activity of PKA, limiting the proliferative 
potential of epithelial hair follicle stem cells (17). Nevertheless, the connection of PKA 
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signaling to TICs and the stem-like state is poorly understood and the exploitation of this 
pathway as a differentiation-based cancer therapy has not been explored.
Results
Identification of agents that induce an MET in mammary epithelial cells
Human breast cancers are characterized by cells exhibiting various degrees of epithelial and 
mesenchymal properties as revealed by the expression pattern of markers such as 
cytokeratins and vimentin (Fig S1). Almost 85% of the carcinomas we examined showed 
varied expression patterns of cytokeratins, indicating that the loss of epithelial properties is a 
commonly occurring event. Notably, ∼10% of the carcinomas we examined exhibited high 
degrees of intra-tumoral heterogeneity, created in part by the presence of subpopulations of 
neoplastic cells that exhibit both epithelial and mesenchymal properties. These are 
reminiscent of cells that have undergone an EMT, resembling TICs that possess a higher 
tumor-initiating propensity and an increased resistance to chemotherapy (18). To model the 
behavior of these subpopulations of carcinoma cells from human basal-like breast cancers, 
we used HMLE immortalized human mammary epithelial cells (19), which display an 
epithelial morphology, express E-cadherin at adherens junctions and low levels of 
mesenchymal markers such as vimentin and fibronectin. They also exhibit a CD44lo/CD24hi 
cell surface marker phenotype that is characteristic of previously reported cells that lack 
stemlike properties (non-CSCs) (20). We also used their spontaneously arising mesenchymal 
derivatives, termed NAMEC8 (N8) cells (21). Relative to their HMLE counterparts, N8 cells 
express mesenchymal markers such as vimentin and fibronectin as well as the EMT-inducing 
transcription factors Snail and Zeb1 at higher levels, lack expression of E-cadherin and 
prominent cell junctions, and display a CSC-like CD44hi/CD24lo cell surface marker profile 
(Fig 1A to C). They also possess a greater propensity to form mammospheres (Fig 1D, E), 
which is often used as an in vitro surrogate assay for the stemness of mammary epithelial 
cells. They are more efficient at migration through a transwell membrane and invasion 
through a Matrigel-coated Boyden chamber membrane (Fig 1F and G); both in vitro assays 
represent models of cancer cell invasiveness in vivo. N8 cells are also more resistant to 
treatment with chemotherapeutic drugs such as doxorubicin and paclitaxel (Fig 1H, I), as 
shown previously (21). Hence, two cell types represent epithelial and mesenchymal 
derivatives of mammary epithelial cells of common origin that were used to model the two 
cell states and how they impact tumor initiation and progression.
To search for agents that can induce an MET, we performed a screen to identify compounds 
that could induce transcription of CDH1, which encodes E-cadherin, a key epithelial protein, 
in N8 cells. As a reporter for the activity of the CDH1 gene, we constructed a lentiviral 
vector that expresses a portion of the CDH1 promoter fused to luciferase (Fig S2A). We 
performed a screen using a 400-compound library for agents that were able to induce the 
CDH1-driven luciferase expression in N8 cells (Fig S2B). Most striking was the behavior of 
forskolin (Fsk), an adenylate cyclase activator that induced a 40-fold increase in luciferase 
activity (Fig S2C). Another adenylate cyclase activator, cholera toxin (CTx), was also able to 
induce an increase in luciferase activity (Fig S2D), suggesting that activation of adenylate 
cyclase could induce the acquisition of epithelial properties.
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Forskolin or Cholera Toxin and the induction of an MET in mammary epithelial cells
We found that treatment of N8 cells in monolayer culture with either CTx or Fsk for a period 
of 14 days induced the formation of islands of cells with the characteristic cobblestone 
morphology of epithelial cells; such cells acquired the expression of E-cadherin at adherens 
junctions along with a loss of mesenchymal markers such as vimentin (Fig 1A–C). Also, the 
cell-surface marker expression profile of the N8 cells switched from a stem-like CD44hi/
CD24lo to a non-stem CD44lo/CD24hi phenotype following this treatment (20) (Fig 1B). 
These shifts were accompanied by a 100-fold increase in CDH1 mRNA levels, as well as 4-, 
5- and 7-fold decreases in the mRNAs levels of Snail, Twist1 and Zeb1 EMT-inducing 
transcription factors (EMT-TFs) to 25%, 20% and 14%, respectively, of the N8 cells before 
the transition (Fig S3A and B). Treatment of N8 cells with either CTx or Fsk resulted in a 
near-complete loss of mammosphere-forming ability (Fig 1D and E), as well as their ability 
to migrate and invade (Fig 1F and G). There were no significant differences in the rates of 
proliferation between the N8 cells and their CTx- and Fsk-treated derivatives (Fig S3C). Of 
additional interest, withdrawal of CTx after 14 days of treatment led to cell populations that 
continued to reside in an epithelial state for >2 months in culture.
Reversion to an epithelial state, ostensibly similar to that of HMLE cells, rendered the N8 
cells 8 times as sensitive to killing by doxorubicin (lowered the median inhibitory 
concentration (IC50) from 1.39µM to 0.159µM), and 13 times as sensitive to paclitaxel 
(lowered the IC50 from 4.79µM to 0.35µM) (Fig 1H and I). Additionally, the induced MET 
also resulted in increased sensitivity to a range of chemotherapeutic drugs and inhibitors 
including methotrexate, HSP90 inhibitors, proteasome inhibitors, and epidermal growth 
factor receptor-mitogen-activated protein kinase (EGFR/MAPK) pathway inhibitors, as 
observed when we screened against two small molecule libraries (Selleck Anti-cancer 
Compound Library and Enzo Kinase Inhibitor Library)(Fig S4). Hence, the induction of an 
MET rendered the N8 cells more sensitive to a range of drugs and inhibitors, pointing to its 
utility as a means of overcoming therapeutic resistance. Additionally, it also reinforces the 
notion that mesenchymal cells are more resistant to a range of cytotoxic agents.
We then performed mRNA sequencing (mRNA-Seq) to compare the global gene expression 
profiles of the mesenchymal N8 and the reverted N8-CTx cells in order to view the 
transcriptional changes that occur following the induction of MET. As determined by 
differential gene expression (Fig 1J, Table S1 and S2) and principal component analyses 
(Fig S3D), the N8-CTx cells assume a gene expression profile that is almost completely 
converted to that of the epithelial HMLE cells and significantly differ from the mesenchymal 
N8 cells (Fig 1J). Gene set enrichment analyses showed that the changes in gene expression 
from N8 to the N8-CTx cells are highly similar to several previously published EMT/MET 
gene signatures (22–24) (Fig S3E).
Taken together, these observations demonstrated a genuine transition of the N8 cells from a 
mesenchymal-like state to a bona fide epithelial state, rendering these cells more sensitive to 
a variety of drugs with potentially important therapeutic implications.
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Effects of Forskolin and Cholera Toxin on intracellular cAMP levels and PKA
To confirm that both Fsk and CTx were working through alteration of cAMP levels, we 
measured the levels of this second messenger in both HMLE and N8 cells using liquid 
chromatography - mass spectrometry (LC-MS). Treatment with CTx resulted in a 6–8-fold 
increase in the intracellular levels of cAMP, which could be dampened by exposure to 
SQ22536, an inhibitor of adenylate cyclase, the enzyme responsible for the formation of 
cAMP (Fig 2A).
The major downstream targets of cAMP are exchange proteins activated by cAMP 
(EPAC1/2) (25), cyclic nucleotide gated ion channels which are primarily found in cells of 
the kidney, heart, testis and central nervous system (26); and the most commonly studied 
downstream effector, protein kinase A (PKA) (11). To delineate the downstream pathways 
that are activated in response to increase in cAMP levels, we treated N8 cells with two 
cAMP analogs – 8-Bromoadenosine-3’,5’-cyclic monophosphate (8-Br-cAMP), which is 
known to preferentially activate PKA (27) or 8-(4-chlorophenylthio)-2’-O-
methyladenosine-3’,5’-cyclic monophosphate (8-CPT-2Me-cAMP), which is a selective 
activator of the exchange proteins activated by cAMP (EPAC) (28). As was seen with Fsk/
CTx, treatment with 8-Br-cAMP was also able to induce an MET in N8 cells, whereas 8-
CPT-2Me-cAMP treatment had no effect on their mesenchymal properties (Fig 2B). This 
allowed us to conclude that PKA, rather than the cAMP-activated exchange proteins, was 
more likely to play a central role in the MET process.
Knockdown of the catalytic subunit of PKA using two different shRNAs (Fig S5A) 
abrogated the CTx-induced MET process in N8 cells, as demonstrated by their inability to 
develop a clear epithelial morphology, acquire junctional E-cadherin, and to shed 
mesenchymal markers such as fibronectin (Fig 2C, D). Moreover, treatment of these PKA-
knockdown cells with CTx failed to induce an effective transition from the CD44hi/CD24lo 
stem-like state to the CD44lo/CD24hi non-stem-like state, which was otherwise observable in 
the absence of PKA knockdown (Fig 2E). These results further reinforced the important role 
of PKA in the MET process.
We proceeded to test whether PKA activity, independent of cAMP, was sufficient to induce 
an MET. Thus, we ectopically expressed a doxycycline-inducible constitutively active, 
cAMP-independent mutant form of PKA (caPKA) (29) in N8 cells and found that it was 
capable of inducing a reversion to the epithelial state in 7–10 days (Fig 2F). Hence, it 
appears as though PKA is both necessary and sufficient to induce an MET in the N8 cells.
We tested the role of CTx/Fsk in inducing an epithelial state in other cell systems to assess 
the generality of our observations. Removing CTx from the standard culture medium of 
MCF10A immortalized human mammary epithelial cells (30), caused them to acquire 
mesenchymal properties, lose cell-cell adherens junctions, lose their characteristic 
cobblestone morphology, gain a CD44hi/CD24lo cell surface marker profile. They also lost 
E-cadherin expression and exhibited an increase in expression of Zeb1, Vimentin and 
Fibronectin (Fig S6A–E). Re-addition of CTx or forced expression of the constitutively 
active PKA mutant (caPKA) led to the re-acquisition of epithelial features (Fig S6A–E). 
Moreover, the MCF10A cells that lost epithelial properties upon CTx withdrawal were 4 
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times as resistant to treatment with doxorubicin, extending our observations made in N8 
cells that the mesenchymal variants were more resistant to conventional chemotherapeutic 
agents (S6F).
We then proceeded to test the role of CTx/Fsk in a series of other cell lines. MCF7-Ras 
human breast cancer cells (31) can be induced to undergo an EMT through the ectopic 
expression of EMT-inducing transcription factors, such as Slug. Co-treatment of the cells 
undergoing an EMT with CTx led to a 48-hour delay in the acquisition of mesenchymal 
morphology and CD44hi cell-surface marker expression (Fig S7A). Similarly, the ability of 
HMLE-Ras cells to undergo an EMT upon ectopic expression of Zeb1 was also hampered 
upon co-treatment with CTx (Fig S7B). PANC1 pancreatic adenocarcinoma cells undergo an 
EMT upon treatment with TGF-β1 for 48 hours (32). Co-treatment of PANC1 cells 
undergoing an EMT with either CTx or Fsk delayed the ability of TGF-β1 to induce an 
EMT by 48–72 hours, enabling the temporary retention of epithelial properties (Fig S7C, D).
Treatment with CTx or Fsk induced the acquisition of epithelial properties in a range of cell 
lines that have mesenchymal traits including the Hs578T triple-negative breast cancer cell 
line (Fig S8A), the SUM149 breast cancer cell line (Fig S8B), the NCI-H596 lung 
adenosquamous carcinoma cell line (Fig S8C) and the mesenchymal EpCAMlo CD24lo 
fraction of the EF021 ovarian carcinoma cell line (Fig S8D). Induction of epithelial 
properties was also observed in PB3 cells (Fig S8E), which constitute an aggressive cell line 
isolated from mammary tumors of the genetically engineered MMTV-PyMT mouse model 
of breast cancer, in which the expression of the oncogene is driven by the mouse mammary 
tumor virus promoter (33). Finally, we note that others have recently reported that forskolin 
promotes the maintenance of an epithelial morphology in primary human mammary 
epithelial cells, the absence of which led spontaneously to acquisition of mesenchymal 
attributes, such as downregulation of E-cadherin expression and upregulation of 
mesenchymal markers (34).
Taken together, these data signify the importance of PKA signaling in maintaining epithelial 
characteristics in a variety of normal and neoplastic epithelial cells. These data give an 
indication that these responses might be a general property of cAMP-induced activation of 
PKA in the reversal of phenotypes created by activation of an EMT program.
Although CTx was able to induce entrance of the N8 cells and a range of other cell systems 
into a stably maintained epithelial state, there were a few models in which neither CTx nor 
Fsk was able to do so, namely the MDA-MB-231 and SUM159 human breast cancer cell 
lines, amongst others. These cell lines are maintained in the mesenchymal state through the 
deletion or stable silencing of several key epithelial genomic loci, including the repression of 
E-cadherin through strong DNA promoter hypermethylation (35). Hence, although the 
observed effects of PKA activation are applicable to some breast cancer lines and other 
carcinomas, they are not universal and depend instead on the specific genetic or epigenetic 
state of the cells.
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Essential role of PKA-induced activation of PHF2 in MET
PKA is known to act on many substrates in both the cytoplasm and nucleus (36). Treatment 
of HMLE and N8 cells with CTx resulted in an immediate increase in the presence of both 
isoforms of the catalytic subunit in the nucleus (Fig S9A and B), which suggested that PKA 
might be regulating nuclear substrates following activation by cAMP. The most well-studied 
substrate of PKA, CREB1, translocates to the nucleus upon phosphorylation by PKA at 
Ser-133, thereafter altering the transcription of hundreds of target genes (37). In fact, about 
300 distinct physiologic stimuli have been described in the literature that can induce CREB 
Ser-133 phosphorylation (38). It was, therefore, not surprising that CREB was already 
phosphorylated and present in the nucleus of the N8 cells even prior to their treatment with 
either CTx or Fsk (Fig 3A). Note that knockdown of CREB1 using at least two shRNAs (Fig 
S5C) did not affect the ability of CTx to induce an MET in the N8 cells (Fig 3B). Moreover, 
loss of CREB1 alone induced a partial MET in N8 cells (Fig 3B), consistent with previous 
reports of its role in the induction of an EMT (39, 40). From these observations, it was 
obvious that CREB1 did not play an important role in the PKA-induced MET. We then 
assessed the localization of Gli1, Gli2 and Gli3, which have been previously reported to be 
PKA substrates that are retained in the cytoplasm following phosphorylation (41), and found 
no retention of any of the Gli proteins in the cytoplasm following treatment with CTx or Fsk 
(Fig S9C). These observations indicate that the Gli proteins may not play a role in the 
observed PKA-induced MET.
Having explored the two most commonly reported nuclear substrates of PKA, we then chose 
to focus on PHF2, an H3K9 histone demethylase, which is known to become activated upon 
phosphorylation by PKA (42). We found that knockdown of PHF2 expression in N8 cells 
using either of two shRNAs (Fig S5B) phenocopied the effects of PKA knockdown in that it 
prevented CTx-induced mesenchymal-epithelial transition (Fig 3C and D). In contrast, 
knockdown of PHF2 did not alter the ability of HMLE cells to undergo an EMT (Fig 3F and 
G), indicating that this enzyme, while necessary for induction of an MET, apparently plays 
no role in the reverse process -- the EMT, suggesting that it is specifically important for the 
derepression of silenced epithelial genes through its function as a H3K9 histone 
demethylase.
PHF2 can be phosphorylated by PKA at four serine residues in its C-terminus (42) (Fig 3E). 
Accordingly, we engineered a phospho-mimetic form of PHF2 in which all four of these 
serines were replaced by aspartate residues. While expression of this mutant in N8 cells was 
not sufficient on its own to induce an MET, the phospho-mimetic PHF2 was able to 
accelerate the rate of CTx-induced transition from the mesenchymal to the epithelial state 
from 14 days to 6–7 days (Fig 3H, I). Hence, while PHF2 is essential for MET, it appears to 
be only one of the effectors of PKA operating during induction of epithelial transition.
To test whether PHF2 can be directly phosphorylated by PKA in our system, we performed 
an immunoprecipitation of PHF2 followed by immunoblotting using an antibody that 
recognizes phospho-PKA substrate motif. As shown in Fig 3J, 24 hours after treatment of 
N8 cells with CTx, phosphorylation of PHF2 by PKA can be observed, providing evidence 
that PKA phosphorylates PHF2 in the N8 cells. Together these results suggest an important 
role for PHF2 as a PKA substrate in the induction of an MET.
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PKA-induced activation of PHF2 and the epigenetic reprogramming of mesenchymal cells
The H3K9me2 and H3K9me3 marks have been associated with repression of gene 
transcription (43). Given the previously reported role of PHF2 as an H3K9me2/3 
demethylase, we performed chromatin immunoprecipitation followed by deep sequencing 
(ChIP-Seq) using antibodies against the H3K9me3 and H3K9me2 marks to observe the 
presence of these marks in untreated N8 cells as well as CTx-treated counterparts in which 
PHF2 is active. In addition we also performed ChIP-Seq for PHF2, comparing genome-wide 
occupancy in N8 cells to the N8-CTx cells. We did so in order to monitor PHF2-associated 
alterations that might enable phenotypic shifts from the mesenchymal to epithelial states, 
including shifts that might relieve the H3K9-mediated silencing of epithelial genes.
As seen in Fig 4A, there was a striking inverse correlation at specific loci of the presence of 
PHF2 with the repressive H3K9me2 or H3K9me3 marks. This suggests that presence of this 
demethylase may, on it own, suffice to relieve histone-mediated transcriptional silencing. As 
previously reported, PHF2 appears to occupy the promoter region of genes where it 
recognizes the H3K4me3 histone mark (Fig 4B) (9). Interestingly, the total H3K9me3 
counts (greater than 4-fold enrichment above control) in N8-CTx cells was almost half of the 
total counts of the same mark in N8 cells (35,455 vs 18,675). Similarly, the total H3K9me2 
counts in N8-CTx cells were also less than a half of that in the N8 cells (1295 vs 473). As 
shown in the representative circos plots, these data indicate a widespread loss of H3K9-
mediated repression of genomic regions upon treatment of N8 cells with CTx and 
subsequent activation of PHF2 (Fig 4C).
We then sorted for genomic regions present in the N8-CTx but not N8 cells that contained 
PHF2 binding and lacked repressive H3K9me2/3 marks (Table S3). This provided us with a 
list of genomic regions that were relieved of H3K9me2/3-mediated silencing in the N8-CTx 
cells, as compared to the N8 cells, owing to PHF2 occupancy. To ensure that these changes 
were specific for the loss of PHF2, we performed ChIP-Seq for H3K9me2/3 and PHF2 in 
CTx-treated N8 cells that had an shRNA against PHF2 preventing the MET (Table S4). 
These cells that remained morphologically mesenchymal also demonstrated a similar 
epigenetic profile to N8 cells with an overlap of 11,807 peaks than the reverted N8-CTx 
cells, which had an overlap of 6864 peaks. Hence the list of altered genomic regions outlined 
in Table S3 represents genes that were relieved of H3K9-mediated repression upon CTx-
induced activation of PHF2. This suggests that PHF2 activity could be directly responsible 
for the derepression of these genes that are characteristic of the epithelial cell state. In 
addition, the expression values of genes that correspond to these genomic loci were also 
measured in reverted N8-CTx (epithelial) and parental N8 (mesenchymal) cells by RNA-seq 
which verified that gain of PHF2 occupancy and loss of H3K9 marks did indeed lead to 
increased expression (Table S3).
Several genes that play a major role in the phenotype and profile of cells in the epithelial 
state were activated by CTx treatment. Amongst the list of genes that were relieved of 
silencing upon treatment with CTx include CDH1 and CDH3 (among other cadherin genes) 
that code for E-cadherin and P-cadherin (Fig S10A), respectively, which are essential 
components of adherens junctions and hallmark proteins of basal epithelial cells; KRT8 and 
KRT18 (Fig S10B), whose gene products are characteristic components of the cytoskeleton 
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of epithelial cells; and AJAP1 and CLDN4 (Fig S10C, D), which specify genes coding for 
constituents of adherens and tight junctions that are formed by epithelial but not 
mesenchymal cells. Other regions include the TP63 gene (Fig S10E) whose product is a 
hallmark transcription factor of basal mammary epithelial cells and ITGB2, ITGB6 (Fig 
S10F) and ITGB8, which code for integrins that are typically expressed on epithelial cells.
These observations reveal a mechanism by which activation of this demethylase enables the 
transcription of genes that induce an MET and ultimately define the state of the cells.
Activation of PKA and the differentiation of TICs in vivo
We tested the tumor-initiating ability of cells that have been induced to undergo an MET by 
activation of PKA in vitro. We transplanted at limiting dilutions the neoplastic, RAS-
transformed derivatives of HMLE, N8 and the reverted N8-CTx cells, termed HMLE-Ras, 
N8-Ras, and N8-CTx-Ras, into the mammary fat pads of NOD/SCID mice. As anticipated, 
the frequency of tumor-initiating cells in the N8-Ras cells was far greater than in the HMLE-
Ras cell population, in this case 100-fold higher. Significantly, the N8-CTx-Ras cells were as 
inefficient at tumor-initiation as the HMLE-Ras cells (Fig 5A). The primary tumors that 
arose upon orthotopic mammary stromal fat pad implantation of N8-Ras tumors spawned 20 
to 30 micrometastases in the lungs by 12 weeks following implantation. This property was 
completely lost upon induction of an MET by CTx treatment prior to transplantation (Fig 5C 
and Fig S11A), which nevertheless formed primary tumors of comparable size (Fig 5B). 
Moreover, this confirmed previous observations that the phenotypic state of these cells prior 
to neoplastic transformation strongly influenced their behavior following transformation.
To better mimic a clinical scenario, we next asked how the induction of an MET would 
impact pre-established tumors derived from mesenchymal N8 cells. While we wished to 
pharmacologically treat mice that already had established N8-Ras tumors, CTx is too toxic 
to be administered systemically, and the rapid clearance and poor pharmacodynamics of Fsk 
made it difficult to study its effects upon systemic administration. Such difficulties in 
treating mice with PKA agonists have also been reported previously (44, 45). For this 
reason, we focused our efforts on studying the proof-of-principle effects of PKA activation 
in vivo using the doxycycline-inducible version of constitutively active PKA (caPKA). Thus, 
we induced expression of the caPKA in already-formed N8-Ras tumors of 5mm diameter 
(Fig 5D). Upon visual inspection, the tumors that had been exposed for 14 days to 
doxycycline contained pasty, fluid-filled necrotic cores when compared to the tumors that 
had never been exposed to doxycycline, the latter being solid with a hard center of viable 
cells. Tumors from mice that received doxycycline weighed less than those that did not 
receive any (Fig 5F). Moreover, those tumors in which expression of caPKA had been 
induced developed a more differentiated histomorphology as revealed by H&E staining of 
tumor sections (Fig S11B, C). Importantly, when tumors were harvested and subjected to 
FACS analysis, the doxycycline-treated tumors showed a decrease in expression of the CD44 
cell-surface marker associated with the stem-like population (20) in contrast to the untreated 
tumors (Fig S11D).
Strikingly, secondary transplantation of cells isolated from the doxycycline-exposed tumors 
at limiting dilutions revealed a ∼20-fold loss of tumor-initiating ability (Fig 5E), showing 
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that activation of PKA induces differentiation of TICs, diminishing their ability to 
subsequently seed new tumors. This result demonstrates that constitutive expression of PKA 
for a 14-day period in a growing tumor suffices on its own to induce the differentiation of 
TICs in the tumor, reducing the tumor-initiating properties of its associated cells as indicated 
by their subsequent inability to propagate tumors upon secondary transplantation.
Discussion
Cyclic AMP and its main effector, PKA, have been studied for four decades in a variety of 
cell-biological and physiologic settings, where its effects in activating a number of distinct, 
tissue-specific traits have been repeatedly documented (11). A role that it might play in 
governing the epithelial cell state and thus suppressing entrance into the alternative 
mesenchymal state in breast cancers has not been described. The present work makes its 
clear that this second messenger and its main effector, PKA, play a key role in determining 
this epithelial versus mesenchymal balance of mammary epithelial cells, as well as epithelial 
cells of other tissues. Indeed, in light of these results, it becomes plausible that maintenance 
of the residence of cells in an epithelial state depends on tonic elevated levels of intracellular 
cAMP. In retrospect, it now seems likely that the use of cholera toxin as an ingredient in the 
tissue culture medium of various epithelial cell types (including cells of the epidermis, 
mammary gland and bronchus (46, 47)) was motivated by the observation that loss of such 
cells in culture was accompanied by an overgrowth of fibroblast-like cells (46).
These results collectively indicate a role for PKA in the differentiation of TICs by enforcing 
residence in the epithelial state and preventing or reversing the EMT program. Although 
PKA can act via a large number of substrates, we identified PHF2 as an important 
downstream effector of PKA that mediates the induction of epithelial characteristics through 
epigenetic reprogramming to a chromatin state that is more favorable for residence in the 
epithelial state. We find that activating this histone demethylase enables PKA to induce the 
transcription of genes that play a role in the entrance into and maintenance of residence in 
the epithelial state.
The EMT program is known to represent one defined route for the generation of both normal 
and neoplastic epithelial stem cells (6, 7, 48). The observations that PKA-induced activation 
of PHF2 can either reverse or curtail this program present an opportunity to exploit such a 
mechanism for therapeutic gain. Indeed the differentiation of TICs through the induction of 
an MET is an attractive proposition - one that could be pursued through the induced increase 
of intracellular cAMP levels, activation of PKA, or activation of PHF2. Nonetheless, it is 
likely that many such approaches will result in widespread side-effect toxicities owing to the 
multitude of signaling pathways that are activated downstream of cAMP increase (11). 
Specific activation of the PHF2 histone-modifier enzyme may serve as a means of 
derepressing genes that are essential for the differentiated epithelial state without eliciting 
many of the toxicities of induced cAMP increases. Along the same lines, identification of a 
histone methyltransferase that counteracts PHF2 function may also provide an attractive 
target for therapeutic inhibition, a strategy that has proven successful in the case of DOT1L 
inhibition against MLL-driven leukemias (49). The role of the G9a histone 
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methyltransferase in establishing the H3K9me2 mark for repression of the CDH1 promoter 
in breast cancer cells has been reported previously (50).
This study provides mechanistic insight into the benefits of targeting such an enzyme in 
epithelial tumors, preventing the constituent cells from undergoing an EMT and thereby 
acquiring aggressive characteristics, including increases in the numbers of TICs. The 
pathways explored in this study provide novel insight into the functions of PKA in the 
induction of an MET and the differentiation of the more aggressive TICs within a tumor. 
This study reveals a new direction for targeting the TIC population through epigenetic 
rewiring that ultimately results in their differentiation and increased susceptibility to 
conventional chemotherapeutic drugs.
Materials and Methods
Cell Culture and treatments
HMLE, NAMEC8 and all derived cell lines were grown in MEGM medium (Lonza, USA), 
MCF10A cells were grown in DMEM/F12 containing 5% horse serum (Sigma USA; 
H0146), EGF 20ng/mL, Hydrocortisone 0.5mg/mL, Cholera Toxin 100ng/mL and insulin 
10µg/mL. EF021 and H596 cells were grown in RPMI containing 10% fetal bovine serum. 
MCF7Ras cells were grown in DME containing 10% fetal bovine serum. Hs578T were 
grown in DME containing 10% fetal bovine serum and 10µg/mL insulin. Cells were treated 
with either 100ng/mL of Cholera Toxin (Calbiochem USA; 227036), which was replenished 
every two days, or 1uM Forskolin (Tocris Biosciences USA; 1099), which was replenished 
daily over a period of 14 days. Cells were split to a ratio of 1:6 every 3 days during the 
treatments.
Screening
For the CDH1 reporter screen 500 N8 cells bearing wtCDH1 promoter luciferase were 
seeded into 384-well plates in a volume of 40ul. 24h later, 100nl of each compound (200uM 
stock) were added using a CyBio liquid handler, resulting in a final screen concentration of 
0.5uM. Four days later, the plates were read for either firefly luciferase activity (Pierce, Cat# 
16177) or CellTiter Glo (Promega USA, Cat# G7572). The Enzo compound library (Plate A 
and Plate B; 451 compounds, including repeats) was obtained from the Koch Institute 
Screening Facility at MIT. Firefly luciferase and CellTiter Glo assays were performed in 
triplicates.
The vulnerabilities of the reverted cells were assessed by screening against the Selleck anti-
cancer compound library (400 compounds) and the Enzo kinase library (80 compounds) at 
the Koch Institute Screening Facility at MIT. 1000 N8 or N8-CTx cells were seeded in 384-
well plates in a volume of 50ul. 24h later, 50nl of each compound was added to assay a 5-
point dose response. Three days later, the plates were read for CellTiter Glo, assays were 
performed in duplicate.
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Flow Cytometry
Cells were prepared according to standard protocols and suspended in 2% IFS/PBS. DAPI 
(Life Technologies USA; D1306) was used to exclude dead cells. Cells were sorted on BD 
FACSAria SORP and analysed on BD LSRII, using BD FACSDiva Software (BD 
Biosciences, USA). Antibodies used were anti- CD44-PE-Cy7 (Biolegend USA #103029), 
anti- CD24-PE (BD Biosciences USA #555428), anti-CD45-Pacific Blue (Biolegend USA 
#103125), anti-CD31-Pacific Blue (Biolegend USA #102421).
Mammosphere/Tumorsphere Culture
Mammosphere/tumorsphere culture was performed as previously described (51). 1000 cells 
were seeded per well of a 96-well Corning Ultra-Low attachment plate (Corning USA; 
CLS3474) in replicates of 10, sphere numbers were counted between days 8 to 12.
Migration and Invasion Assays
Twenty-five thousand cells were seeded into 24-well cell culture inserts with 8 µm pores 
(BD Falcon, USA). After 12 to 24 hours, the cells on the upper surface of the filters were 
removed with a cotton swab. For visualization, cells on lower filter surfaces were fixed and 
stained with a Diff-Quick staining kit (Dade Behring/Siemens, Germany). Three to five 
fields per filter were counted. Data are presented as migrated cells per field.
RNA preparation and qRT-PCR analysis
Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen USA; 74136) and reverse 
transcription was performed with the High Capacity RNA-to-cDNA Kit (Life Technologies 
USA; 4387406), both according to the manufacturer’s protocols. A cDNA sample prepared 
from 1 µg total RNA was used for quantitative RT-PCR. The PCR reactions were performed 
using the Fast SYBR Green Master Mix (Life Technologies; 4385612), data collection and 
data analysis were performed on the ABI7900 machine (Applied Biosystems, USA) using 
the SDS2.0 and RQ manager software. The thermal cycling parameters for the PCR were as 
follows: 95 °C for 5 min, followed by 45 cycles of 95 °C for 10 sec, 49 °C for 7 sec, and 
72 °C for 25 sec. The relative mRNA quantity was normalized against the relative quantity 
of HPRT1 mRNA in the same sample.
Name Primer sequence in 5’-3’ orientation
E-CADHERIN F – TTGCACCGGTCGACAAAGGACR - TGGATTCCAGAAACGGAGGCC
FIBRONECTIN F - GAGAATGGACCTGCAAGCCCAR - AGTGCAAGTGATGCGTCCGC
VIMENTIN F – ACCCGCACCAACGAGAAGGTR - ATTCTGCTGCTCCAGGAAGCG
SNAI1 F - CTGGGTGCCCTCAAGATGCAR - CCGGACATGGCCTTGTAGCA
SNAI2 F – TACCGCTGCTCCATTCCACGR - CATGGGGGTCTGAAAGCTTGG
TWIST1 F - TGCGGAAGATCATCCCCACG
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Name Primer sequence in 5’-3’ orientation
R - GCTGCAGCTTGCCATCTTGGA
ZEB1 F – TGCACTGAGTGTGGAAAAGCR - TGGTGATGCTGAAAGAGACG
HPRTI F- CTCCGTTATGGCGACCCR- CACCCT TTCCAAATCCTCAG
PHF2 F- CCCATGGGTTTTCTCACAGTR- GGCTCCCCTACGACGTTA
PRKACA F- GTGTTCTGAGCGGGACTTTCR- GCCCTGAGAACAGGACTGAG
PRKACB F- AAAGTCTTCTTTGGCTTTGGCR- CCTTCCCTGACCCCTTCTT
Immunofluorescence (cultured cells)
Cells were cultured on dishes containing coverslips for 2–3 days following which coverslips 
were washed in cold PBS, fixed in 4% paraformaldehyde for 10 minutes at 4°C and 
permeabilized in 0.2% tritonX in PBS for 2 minutes. Cells were then washed in PBS, 
blocked for 1 hour at room temperature in PBS containing 3% normal horse serum (Vector 
Labs USA; S-2000). Fixed cells were then incubated with the primary antibody in PBS 
containing 1%BSA solution overnight at 4°C. Cells were washed in PBS three times and 
secondary antibody was added in PBS containing 1%BSA solution for 1–2 hours at room 
temperature in the dark. Cells were washed three times in PBS and were incubated for 2 
minutes in DAPI solution, following which they were washed in PBS and mounted with a 
drop of Prolong Gold antifade reagent (Life Technologies USA; P36961) and coverslipped. 
Slides were imaged on a PerkinElmer Ultraview Spinning Disk Confocal and analyzed using 
Volocity software.
Immunofluorescence (Tissue microarrays)
Slides were rehydrated by incubating in Histoclear solution twice for 5 minutes each, 
followed by incubation in 100% ethanol twice for 5 minutes each, in 95% ethanol twice for 
5 minutes each, 70% ethanol twice for five minutes each, once in 35% ethanol for five 
minutes and in water for 5 minutes. Pressure cooker mediated heat induced epitope retrieval 
was carried out in 250mL of unmasking buffer containing sodium citrate at pH 6. Following 
retrieval, slides were blocked for 30 minutes in PBS containing 3% normal horse serum 
following which they were incubated with primary antibody in blocking solution overnight 
at 4°C. Slides were washed twice with PBS and incubated with secondary antibody at room 
temperature for 1 hour in the dark. Following two PBS washes, 20ul of mounting medium 
was added, coverslipped and stored in the dark for 24 hours before imaging.
Target Company Catalog # host Dilution
E-Cadherin BD Biosciences 610182 mouse 1:500
E-Cadherin Cell Signaling Technologies 3195 rabbit 1:200
Fibronectin BD Biosciences 610078 mouse 1:200
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Target Company Catalog # host Dilution
PKAC-α Cell Signaling Technologies 4782 rabbit 1:100
PKAC- α Abcam ab124390 mouse 10 µg/ml
PKAC-β Santa Cruz Biotechnology sc-904 rabbit 1:100
Vimentin Cell Signaling Technologies 3932 rabbit 1:100
PHF2 Abcam ab154983 mouse 1:50
Proliferation Assays
To measure rate of proliferation, 1000 cells were seeded onto 96-well plate in quadruplicate. 
Proliferation was measured using CyQuant (Life Technologies USA, C7026) according to 
manufacturer’s protocols.
Protein Extraction and Western Blotting
To obtain protein extracts, cells were washed with chilled PBS and scraped from culture 
dishes in aqueous lysis buffer (50mM Tris pH7.5, 150mM NaCl, 10mM EDTA pH8.0, 0.2% 
Sodium Azide, 50mM NaF, 0.5% NP40) containing cOmplete mini protease inhibitor 
cocktail (Roche, USA 04693159001) and stored at −80°C. Following thawing, they were 
centrifuged at top speed on a benchtop centrifuge at 4°C for 20 minutes and the supernatant 
was assayed for protein concentration with Bradford Reagent (Bio-Rad; 500-0006). 30ug of 
total protein were separated by SDS-PAGE on NuPage gels (Invitrogen, USA) and 
transferred to Hybond-P PVDF membrane (GE Healthcare, USA). Membranes were probed 
with specific primary antibodies and antibody-protein complex detected by HRP-conjugated 
secondary antibodies and SuperSignal West Dura Extended Duration Substrate (Life 
Technologies USA; 34075).
Target Company Catalog # host Dilution
E-Cadherin Cell Signaling Technology 3195 rabbit 1:1000
Fibronectin BD Biosciences 610078 mouse 1:1000
PKAC-α Cell Signaling Technology 4782 rabbit 1:1000
PKAC-β Santa Cruz Biotechnology sc-904 rabbit 1:1000
Zeb1 Cell Signaling Technology 3396 rabbit 1:1000
Snail1 Cell Signaling Technology 3879 rabbit 1:1000
Vimentin Cell Signaling Technology 3932 rabbit 1:1000
PHF2 Abcam ab154983 mouse 1:500
P-CREB1 Cell Signaling Technology 9198 rabbit 1:1000
CREB1 Cell Signaling Technology 9197 rabbit 1:1000
Gli1 Santa Cruz Biotechnology sc-20687 rabbit 1:1000
Gli2 Santa Cruz Biotechnology sc-271786 mouse 1:1000
Gli3 Santa Cruz Biotechnology sc-6154 goat 1:1000
p-PKA substrate Cell Signaling Technology 9621 rabbit 1:1000
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Target Company Catalog # host Dilution
PHF2 Cell Signaling Technology 3497 rabbit 1:1000
Cox IV Cell Signaling Technology 4850 rabbit 1:1000
Immunoprecipitation
N8 cells in 15cm dishes were scraped and harvested in 0.5mL ice-cold IP buffer (Cell 
Signaling Technology, USA) containing protease and phosphatase inhibitors (Roche, 
Germany) following which they were sonicated with three pulses on ice. Lysates were spun 
down at 14,000g for 10 minutes and supernatants collected for IP. Anti-PHF2 antibody 
(Catalog# 3497; Cell Signaling Technology, USA) was added at 1:25 and incubated 
overnight at 4°C rotating. The following morning, 40ul of magnetic protein A/G beads 
(Catalog #26162; Thermo Scientific, USA) were added, incubated for 30 minutes on a 
rotator following which beads were washed 5 times using a magnetic separator with cold IP 
buffer. Beads were then boiled in LDS buffer and run on an SDS-PAGE gel followed by 
immunoblotting.
RNAi-mediated knockdown
To generate shRNA expressing plasmids, double-stranded oligonucleotides (oligos) 
encoding the desired shRNA were cloned into a Tet-pLKO-puro lentiviral vector (Addgene, 
plasmid 21915). In the absence of doxycycline, shRNA expression is repressed by 
constitutively expressed TetR protein. Upon the addition of doxycycline to the growth 
media, shRNA expression is triggered resulting in target gene knock-down. The cloning 
vector has a 1.9 kb stuffer that is released by digestion with AgeI and EcoRI. shRNA oligos 
are cloned into the AgeI and EcoRI sites in place of the stuffer.
PKA hairpins
Name Target Sequence
Forward Oligo - full sequence
5’ flank sequence: CCGG
Loop sequence: CTCGAG
3’ flank sequence: TTTTTG
Reverse Oligo - full sequence
5’ flank sequence: AATTCAAAAA
Loop sequence: CTCGAG
3’ flank sequence: (none)
A1 CCCTTCATACCAAAGTTTAAA
5’-
CCGGCCCTTCATACCAAAGTTTA
AACTCGAGTTTAAACTTTGGTAT
GAAGGGTTTTTG-3’
5’-
AATTCAAAAACCCTTCATACCAA
AGTTTAAACTCGAGTTTAAACTT
TGGTATGAAGGG-3’
B1 GACCAACCAATTCAGATTTAT
5’-
CCGGGACCAACCAATTCAGATTT
ATCTCGAGATAAATCTGAATTGG
TTGGTCTTTTTG-3’
5’-
AATTCAAAAAGACCAACCAATTC
AGATTTATCTCGAGATAAATCTG
AATTGGTTGGTC-3’
B3 GTCTCAATAAGGCAATATATT
5’-
CCGGGTCTCAATAAGGCAATATA
TTCTCGAGAATATATTGCCTTATT
GAGACTTTTTG-3’
5’-
AATTCAAAAAGTCTCAATAAGGC
AATATATTCTCGAGAATATATTG
CCTTATTGAGAC-3’
B4 AGACCAACCAATTCAGATTTA
5’-
CCGGAGACCAACCAATTCAGATT
TACTCGAGTAAATCTGAATTGGT
TGGTCTTTTTTG-3’
5’-
AATTCAAAAAAGACCAACCAATT
CAGATTTACTCGAGTAAATCTGA
ATTGGTTGGTCT-3’
B10 GTCATGTAAATGCTGATATTG
5’-
CCGGGTCATGTAAATGCTGATAT
5’-
AATTCAAAAAGTCATGTAAATGC
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Name Target Sequence
Forward Oligo - full sequence
5’ flank sequence: CCGG
Loop sequence: CTCGAG
3’ flank sequence: TTTTTG
Reverse Oligo - full sequence
5’ flank sequence: AATTCAAAAA
Loop sequence: CTCGAG
3’ flank sequence: (none)
TGCTCGAGCAATATCAGCATTTA
CATGACTTTTTG-3’
TGATATTGCTCGAGCAATATCAG
CATTTACATGAC-3’
B12 GTTTAGAGGCTCTGGAGATAC
5’-
CCGGGTTTAGAGGCTCTGGAGAT
ACCTCGAGGTATCTCCAGAGCCT
CTAAACTTTTTG-3’
5’-
AATTCAAAAAGTTTAGAGGCTCT
GGAGATACCTCGAGGTATCTCCA
GAGCCTCTAAAC-3’
PHF2 hairpins
Name Target Sequence Forward Oligo Reverse Oligo
P1 GGAGCCACCTGACATTGTAAA
5’-
CCGGGGAGCCACCTGACATTGTA
AACTCGAGTTTACAATGTCAGGT
GGCTCCTTTTTG-3’
5’-AATTCAAAAAGGAGCCACCTGAC
ATTGTAAACTCGAGTTTACAATGT
CAGGTGGCTCC-3’
P3 TTGCTGACCAGGTCGACAAAT
5’-
CCGGTTGCTGACCAGGTCGACAA
ATCTCGAGATTTGTCGACCTGGTC
AGCAATTTTTG-3’
5’-AATTCAAAAATTGCTGACCAGGT
CGACAAATCTCGAGATTTGTCGA
CCTGGTCAGCAA-3’
CREB1 hairpins
Name Target Sequence
CREB1 ACGGTGCCAACTCCAATTTAC
CREB3 ACAGCACCCACTAGCACTATT
Animal Studies
Research involving animals complied with protocols approved by the MIT Committee on 
Animal Care. For tumor studies, cells suspended in 15µl 30% Matrigel(GFR)/PBS mix (BD 
Biosciences; 356230) were injected into the inguinal mammary gland fat pads of age-
matched female NOD/SCID mice (Jackson Laboratory). Mice were sacrificed after 10 
weeks or when tumors reached a diameter >1 cm. Lung surface metastases were counted 
with a fluorescent microscope.
Chromatin Immunoprecipitation followed by Sequencing
ChIP for PHF2, H3K9me2 and H3K9me3 was carried out using the SimpleChIP® Plus 
Enzymatic Chromatin IP Kit (Catalog# 9005; Cell Signaling Technology, USA) and the 
protocols within. The PHF2 rabbit monoclonal antibody (Catalog#3497; Cell Signaling 
Technology, USA) was used at 1:25 per IP, the H3K9me2 mouse monoclonal (Catalog# 
ab1220; Abcam, USA) and the H3K9me3 rabbit polyclonal antibodies (Catalog#ab8898) 
were used at 1:50 (10ug) per IP. The ChIP DNA was used to prepare libraries for 
sequencing, which was carried out in the Genome Technology Core at the Whitehead 
Institute.
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Library Preparation for Sequencing
To prepare libraries for RNA-Seq, the TruSeq stranded mRNA protocol was followed to 
prep the libraries as described in the kit (Catalog # RS-122–2101, Illumina, USA) manual. 
To prepare libraries for the ChIP-Seq, the TruSeq ChIP protocol was followed as described 
in the kit (Catalog # IP-202–1012, Illumina, USA) manual.
Deep Sequencing and data analysis
Sequencing: Libraries were pooled together and sequenced on the HiSeq 2500 sequencer 
using the Standard sequencing protocols. Images analysis and base calling was done using 
the Standard Illumina pipeline, and then demultiplexed into fastq files. RNASeq paired-end 
reads from Illumina 1.5 encoding were aligned using TopHat (v 2.0.13) (52) to the human 
genome (GRCh37) with Ensembl annotation (GRCh37.75) in gtf format. Differential 
expression was assayed using HTSeq count (53) and DESeq (54). ChIPSeq data were 
aligned to the human genome (GRCh37) using Bowtie2 (v 2.2.5) (55), base encoding as 
above, and peaks were called using MACS2 (v 2.1.0.20150420) (56) with --nomodel option 
and fragment length was determined by strand cross-correlation (using 
phantompeakqualtools https://code.google.com/p/phantompeakqualtools/). Differential 
binding was determined using MACS’ bdgdiff tool. Peaks were annotated using Cis-
regulatory Element Annotation System (CEAS) (57), and ChIPSeq data profiles were 
viewed in ngsplot (58). Overlap between peaks, and with expression data, were determined 
using bedtools (59). ChIPSeq data profiles were viewed in ngsplot (58) and IGV (60).
RNA-seq and ChIP-seq data have been submitted to GEO and are awaiting a GSE ID.
LC/MS-based metabolite profiling
LC/MS analyses were conducted on a QExactive benchtop orbitrap mass spectrometer 
equipped with an Ion Max source and a HESI II probe, which was coupled to a Dionex 
UltiMate 3000 UPLC system (Thermo Fisher Scientific, San Jose, CA). External mass 
calibration was performed using the standard calibration mixture every 7 days. Polar 
metabolites were extracted using 1 ml of ice cold 80% methanol with 10 ng/ml 
phenylalanine-d8 or phenylalanine-13C9-15N as an internal standard. After 10 min vortex and 
centrifugation for 10 min at 10,000g, both at 4°C, samples were dried in a centrifugal 
evaporator. Dried samples were stored at −80°C and then resuspended in 100 µL water; 2.5 
µl of each sample was injected onto a ZIC-pHILIC 2.1 × 150 mm (5 µm particle size) 
column (EMD Millipore). Buffer A was 20 mM ammonium carbonate, 0.1% ammonium 
hydroxide; buffer B was acetonitrile. The chromatographic gradient was run at a flow rate of 
0.150 ml/min as follows: 0–20 min.: linear gradient from 80% to 20% B; 20–20.5 min.: 
linear gradient from 20% to 80% B; 20.5–28 min.: hold at 80% B. The column oven was 
held at 25°C. The mass spectrometer was operated with the spray voltage set to 3.0 kV, the 
heated capillary held at 275°C, and the HESI probe held at 350°C; the sheath gas flow was 
set to 40 units, the auxiliary gas flow was set to 15 units, and the sweep gas flow was set to 1 
unit. To measure cAMP, a positive targeted SIM (tSIM) scan was performed at a resolution 
of 70,000, an AGC target of 1e5, and the maximum injection time at 250 msec. The tSIM 
window was set to a width of 1.0 m/z and centered at 330.05980 m/z, corresponding to the 
[M+H] ion of cAMP. To monitor other endogenous polar metabolites and the internal 
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standard, the tSIM scans were interspersed with positive and negative mode scans in the 
range of 70–1000 m/z, with the resolution set to 70,000, the AGC target at 10 , and the 
maximum injection time at 80 msec. Relative quantitation of polar metabolites was 
performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using a 5 ppm mass 
tolerance and referencing an in-house library of chemical standards.
Statistical Analysis
Data are presented as mean ± SD. A Student’s t test (two-tailed) was used to compare two 
groups (p < 0.05 was considered significant) unless otherwise indicated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Induction of a mesenchymal-to-epithelial transition (MET) upon treatment of N8 cells 
with cholera toxin (CTx) or forskolin (Fsk)
Mesenchymal N8 cells acquire an epithelial morphology as adjudged by their morphology 
(A), loss of a stem-like CD44hi/CD24lo profile to assume a predominantly CD44lo/CD24hi 
profile (B) and expression of E-cadherin at cell junctions and loss of vimentin (C). Reverted 
N2-CTx and N3-Fsk cells lose their ability to form (D, E) mammospheres (mean ± SD, 
p<0.05, n=4), (F) migrate (mean ± SD, p<0.05, n=4) and (G) invade in transwell assays 
(mean ± SD, p<0.05, n=4) and acquire increased sensitivity to treatment with (H) 
doxorubicin and (I) paclitaxel (mean ± SD, p<0.05, n=4). (J) Heatmap of mRNA-Seq data 
demonstrating similarity in gene expression between HMLE, N8 and N8-CTx cells. Data in 
(E), (F) and (G) were analysed by student t-test, (H) and (I) were analysed by Bonferroni 
correction. All scale bars - 25µm.
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Figure 2. cAMP increases activate protein kinase A (PKA), which is both necessary and 
sufficient for the induction of an MET in N8 cells
(A) Mass-spectrometry measurement of cAMP levels in N8 cells that have been treated with 
CTx or Fsk alone and in combination with adenylate cyclase inhibitor SQ (mean ± SD, 
p<0.05, n=3). (B) Treatment of N8 cells with either 8-CPT-2me-cAMP or 8-Br-cAMP to 
identify downstream pathways that are responsible for induction of an MET. Knockdown of 
either PRKACA or PRKACB prevents the ability of CTx to induce an MET in N8 cells as 
observed by changes in (C) morphology, (D) immunofluorescence for E-cadherin and 
vimentin and (E) CD44/CD24 status. (F) Morphological changes of N8 cells undergoing an 
MET upon ectopic expression of an active mutant of PKA (caPKA). Data in (A) were 
analysed using the Student t-test. All scale bars - 25µm.
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Figure 3. The PKA substrate PHF2, but not CREB1, is necessary for the MET-inducing 
properties of CTx
Activation state of CREB1 as measured by levels of p-CREB1 across HMLE and N8 cells 
that have been treated with CTx or Fsk (A). Loss of CREB1 through shRNA-mediated 
knockdown induces a partial MET and permits CTx-mediated complete MET as shown by 
changes in morphology and immunofluorescence (B). shRNA-mediated knockdown of 
PHF2 abrogates the ability of CTx to induce an MET preventing changes in (C) morphology 
and immunofluorescence-based detection of E-cadherin and fibronectin expression as well 
as (D) blocking a shift from the CD44hi/CD24lo state to the CD44lo/CD24hi state. 
Pattabiraman et al. Page 24
Science. Author manuscript; available in PMC 2016 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Expression of a PHF2 phosphomimetic where the C-terminal serines were modified to 
aspartate (E) accelerated the MET transition by 5 days as observed by changes in 
immunofluorescence (F) and quantitative EMT marker analysis by qPCR (G). Effects of 
shRNA-mediated knockdown of PHF2 on the ability of HMLE cells to undergo an EMT 
upon ectopic expression of Zeb1 (H, I) (qPCR data - mean ± SD, p<0.05, n=3). 
Immunoprecipitation of PHF2 followed by immunoblotting with a phospho-PKA substrate 
antibody showing direct phosphorylation of PHF2 by PKA 24hrs after treatment of N8 cells 
with CTx (J). (I) was analysed using the Student t-test. All scale bars - 25µm.
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Figure 4. Activation of PHF2 leads the epigenetic reprogramming of mesenchymal cells
Genome-wide occupancy of H3K9me2, H3K9me3 and PHF2 marks shows the inverse 
correlation between the presence of the histone marks and the demethylase (A), which 
interacts mainly with the promoter and the first intronic region of genes (B). Circos plots of 
representative chromosomes 5 and 8 show widespread changes in the H3K9me2 and 
H3K9me3 profiles (C).
Pattabiraman et al. Page 26
Science. Author manuscript; available in PMC 2016 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. PKA-induced MET is sufficient to deplete the tumor-initiating ability of N8-Ras cells in 
vivo
(A) Table outlining differences in tumor-initiating ability of HMLE-Ras, N8-Ras and N8-
CTx-Ras cells upon limiting dilution transplantation into NOD/SCID mice. Tumors that 
arose from transplantation of 2×106 cells were or similar size (B) with only the N8-Ras cells 
bring capable of forming micrometastases (C) (Each dot represents one mouse; data 
analysed using Student t-test; p<0.05, n=10). (D) Panel showing experimental outline to test 
the tumor-initiating ability of N8-Ras cells upon transient in vivo expression of PKA 
showing a (E) 20-fold decrease in tumor-initiating ability upon secondary transplantation 
with (F) no significant differences in the tumor volume. (Each dot represents one mouse; 
data analysed using Student t-test; p<0.05, n=10).
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